Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure

Journal of Parenteral and Enteral Nutrition

Volumn 42, Issue 7, 2018, Pages 1156-1167

  Roychowdhury, Sanjoy ^a   Cadnum, Jennifer ^b   Glueck, Bryan ^a   Obrenovich, Mark ^b   Donskey, Curtis ^b,c   Cresci, Gail A M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotics; butyrate, Clostridium difficile, innate immunity, intestine, microbiome, prebiotic, probiotics

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CLINDAMYCIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PREBIOTIC AGENT; TIGHT JUNCTION PROTEIN; VANCOMYCIN; ANION TRANSPORT PROTEIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BUTYRIC ACID DERIVATIVE; CLOSTRIDIUM DIFFICILE ENTEROTOXIN B RECEPTOR; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; PROBIOTIC AGENT; STARCH;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASCENDING COLON; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL MICROBIOME; BACTERIAL OVERGROWTH; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DYSBIOSIS; FAECALIBACTERIUM PRAUSNITZII; FEMALE; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; INFECTION RISK; INNATE IMMUNITY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA ANALYSIS; TREATMENT DURATION; ANIMAL; CHEMISTRY; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; COLON; DISEASE MODEL; FECES; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; POTATO; SPRAGUE DAWLEY RAT;

ANIMALS; ANION TRANSPORT PROTEINS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BUTYRATES; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; DYSBIOSIS; FAECALIBACTERIUM PRAUSNITZII; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; IMMUNITY, INNATE; PREBIOTICS; PROBIOTICS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SOLANUM TUBEROSUM; STARCH; TIGHT JUNCTION PROTEINS;

EID: 85041190343     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1002/jpen.1053     Document Type: Article

References (45)

1. Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis. 2016;16:447
2. Sehulster L, Chinn RYW. Guidelines for environmental infection control in health-care facilities. MMWR Recomm Rep. 2003;52(RR10):1-42. Available from: http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_excerpt.html
3. Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathogens. 2013;5:23
4. Scott KP, Martin JC, Duncan SH, Flint HJ. Prebiotic stimulation of human colonic butyrate-producing bacteria and Bifidobacteria, in vitro. FEMS Microbiol Ecol. 2014;87:30-40
5. Backhed F, Ley R, Sonnenburg J, Peterson D, Gordon J. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920
6. Hooper L, Midtvedt T, Gordon J. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283-307
7. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079-1087
8. Theriot CM, Koenigsknecht MJ, Carlson PE, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114
9. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51:2884-2892
10. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8:e1002995
11. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002;217:133-139
12. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr. 2002;73:415s-420s
13. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Dig Dis Sci. 1996;41:727-739
14. Thangaraju M, Cresci G, Anath S, Digby G, Lambert N, Mellinger J, Ganapathy V. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009;69:2826-2832
15. Binder HJ. Role of colonic short-chain fatty acid transport and diarrhea. Annu Rev Physiol. 2010;72:297-313
16. Ploger S, Stumpff F, Penner G, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann NY Acad Sci. 2012;1258:52-59
17. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology 2000;118:724-734
18. Hass R, Busche R, Luciano L, Reale E, Engelhardt WV. Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig. Gastroenterology 1997;112:875-881
19. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-514
20. Miquel S, Martin R, Rossi O, et al. Faecalibaterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2014;16:255-261
21. US Environmental Protection Agency Office of Pesticide Programs. Standard Operating Procedure for Production of Spores of Clostridium difficile for Use in the Efficacy Evaluation of Antimicrobial Agents, SOP Number: MB-28-04. Office of Pesticide Programs, Microbiology Laboratory, Environmental Science Center: Ft. Meade, MD; June 19, 2014. Available from: https://www.epa.gov/sites/production/files/2014-12/documents/mb-28-04.pdf
22. Duncan SH, Hold GL, Harmsen H, Stewart CS, Flint HJ. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb.nov. Int J Syst Evol Microbiol. 2002;52:2141-2146
23. Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE, Flint HJ. Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol 2006;72:3593-3599
24. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Anaerobically. 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards: Wayne, PA; 2000
25. Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother. 2005;49:3529-3532
26. Cresci G, Thangaraju M, Mellinger J, Liu K, Ganapathy V. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg. 2010;14:449-461
27. Cresci G, Nagy L, Ganapathy V. Lactobacillus GG and tributyrin supplementation reduce antibiotic-induced intestinal injury. J Parent Enteral Nutr. 2013;37:763-774
28. Engevik MA, Engevik KA, Yacyshyn MB, et al. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol. 2015;308:G497-G509
29. Tao L, Zhang J, Meraner P, et al. Frizzled proteins are colonic epithelial receptors for C. difficile B. Nature. 2016;538:350-355
30. Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. mBio. 2016;7:e01965-16
31. Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80:62-73
32. Hayashi H, Szaszi K, Coady-Osberg N, et al. Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. J Gen Physiol. 2004;123:491-504
33. Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63:193-202
34. Laval L, Martin R, Natividad JN, et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes. 2015;6:1-9
35. El Feghaly R, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. J Clin Dis. 2013;56:1713-1721
36. Hasegawa M, Yamazaki T, Kamada N, et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol. 2011;186:4872-4880
37. Ryan A, Lynch M, Smith SM, et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog. 2011;7:e1002076
38. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun. 2012;80:2989-2996
39. Buonomo EL, Petri WA. The microbiota and immune response during Clostridium difficile infection. Anaerobe 2016;14:79-84
40. Smythies LE, Maheshwari A, Clements R, et al. Mucosal IL-8 and TGFβ recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J Leukoc Biol. 2006;80:492-499
41. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762-774
42. Perner A, Andresen L, Normark M, Rask-Madsen J. Constitutive expression of inducible nitric oxide synthase in the normal human colonic epithelium. Scand J Gastroenterol. 2002;37:944-948
43. Rath M, Muller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:532
44. Pils MC, Bleich A, Prinz I, et al. Commensla gut flora reduces susceptibiolity to experimentally induced colitis via T-cell-derived interleukin-10. Inflamm Bowel Dis. 2011;10:2038-2046
45. Miquel S, Leclerc M, Martin R, et al. Identification of Metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio. 2015;6:e00300-15